The P21-Activated Kinase 1 and 2 As Potential Therapeutic Targets for the Management of Cardiovascular Disease

International journal of drug discovery and pharmacology Pub Date : 2022-12-21 DOI:10.53941/ijddp.v1i1.179

Honglin Xu, Dingwei Wang, Chiara Ramponi, X. Wang, Hongyuan Zhang

{"title":"The P21-Activated Kinase 1 and 2 As Potential Therapeutic Targets for the Management of Cardiovascular Disease","authors":"Honglin Xu, Dingwei Wang, Chiara Ramponi, X. Wang, Hongyuan Zhang","doi":"10.53941/ijddp.v1i1.179","DOIUrl":null,"url":null,"abstract":"Review\nThe P21-Activated Kinase 1 and 2 As Potential Therapeutic Targets for the Management of Cardiovascular Disease\n\nHonglin Xu, Dingwei Wang, Chiara Ramponi, Xin Wang, and Hongyuan Zhang *\n\n\nMichael Smith building, Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.\n* Correspondence: hongyuan.zhang-3@postgrad.manchester.ac.uk\n \n \nReceived: 20 October 2022\nAccepted: 16 November 2022\nPublished: 21 December 2022\n \n\nAbstract: Group I p21-activated kinases (Paks) are members of the serine/threonine protein kinase family. Paks are encoded by three genes (Pak 1‒3) and are involved in the regulation of various biological processes. Pak1 and Pak2 are key members, sharing 91% sequence identity in their kinase domains. Recent studies have shown that Pak1/2 protect the heart from various types of stresses. Activated Pak1/2 participate in the maintenance of cellular homeostasis and metabolism, thus enhancing the adaptation and resilience of cardiomyocytes to stress. The structure, activation and function of Pak1/2 as well as their protective roles against the occurrence of cardiovascular disease are described in this review. The values of Pak1/2 as therapeutic targets are also discussed.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"24 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of drug discovery and pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53941/ijddp.v1i1.179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Review The P21-Activated Kinase 1 and 2 As Potential Therapeutic Targets for the Management of Cardiovascular Disease Honglin Xu, Dingwei Wang, Chiara Ramponi, Xin Wang, and Hongyuan Zhang * Michael Smith building, Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. * Correspondence: hongyuan.zhang-3@postgrad.manchester.ac.uk Received: 20 October 2022 Accepted: 16 November 2022 Published: 21 December 2022 Abstract: Group I p21-activated kinases (Paks) are members of the serine/threonine protein kinase family. Paks are encoded by three genes (Pak 1‒3) and are involved in the regulation of various biological processes. Pak1 and Pak2 are key members, sharing 91% sequence identity in their kinase domains. Recent studies have shown that Pak1/2 protect the heart from various types of stresses. Activated Pak1/2 participate in the maintenance of cellular homeostasis and metabolism, thus enhancing the adaptation and resilience of cardiomyocytes to stress. The structure, activation and function of Pak1/2 as well as their protective roles against the occurrence of cardiovascular disease are described in this review. The values of Pak1/2 as therapeutic targets are also discussed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

p21活化激酶1和2作为心血管疾病管理的潜在治疗靶点

p21活化激酶1和2作为心血管疾病管理的潜在治疗靶点徐洪林，王定伟，Chiara Ramponi，王鑫，张宏远*，Michael Smith building，曼彻斯特大学生物、医学与健康学院心血管科学系，曼彻斯特，英国*通讯:hongyuan.zhang-3@postgrad.manchester.ac.uk收稿日期:2022年10月20日接收日期:2022年11月16日发布日期:2022年12月21日摘要:I组p21活化激酶(Paks)是丝氨酸/苏氨酸蛋白激酶家族的成员。Paks由三个基因(pak1 - 3)编码，参与多种生物过程的调控。Pak1和Pak2是关键成员，在其激酶结构域中具有91%的序列同一性。最近的研究表明，Pak1/2可以保护心脏免受各种压力的影响。活化的Pak1/2参与维持细胞内稳态和代谢，从而增强心肌细胞对应激的适应和恢复能力。现就Pak1/2的结构、激活、功能及其对心血管疾病发生的保护作用作一综述。本文还讨论了Pak1/2作为治疗靶点的价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International journal of drug discovery and pharmacology

自引率

0.00%

发文量